BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kronenfeld JP, Goel N. An Analysis of Individual and Contextual-Level Disparities in Screening, Treatment, and Outcomes for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1209-19. [PMID: 34611524 DOI: 10.2147/JHC.S284430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Gabere M, Tylor MA, Simoes CC, Dumbauld C, Barro O, Tesfay MZ, Graham AL, Ferdous KU, Savenka AV, Chamcheu JC, Washam CL, Alkam D, Gies A, Byrum SD, Conti M, Post SR, Kelly T, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1042250] [Reference Citation Analysis]
2 Papageorge MV, de Geus SWL, Woods AP, Ng SC, Lee S, McAneny D, Tseng JF, Kenzik KM, Sachs TE. Surveillance Patterns for Hepatocellular Carcinoma among Screening-Eligible Patients in the Medicare Population. Ann Surg Oncol 2022. [PMID: 36057903 DOI: 10.1245/s10434-022-12360-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Zhang Y, Gabere M, Taylor M, Simoes CC, Dumbauld C, Barro O, Chamcheu JC, Post SR, Kelly TJ, Borad MJ, Cannon MJ, Basnakian A, Nagalo BM. Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy.. [DOI: 10.1101/2022.02.25.481685] [Reference Citation Analysis]